Dr. Martens tripped up again as weak third quarter sales trigger another profit warning
Weaker-than-expected Q3 salesUS consumer backdrop deterioratesDr. Martens pulls FY25 guidanceInvestors put the boot into Dr. Martens (DOCS) after the iconic footwear brand downgraded its year-to-March 2024 EBITDA (earnings before interest, tax, depreciation and amortisation) guidance once again and withdrew previous guidance for high single digit sales growth in full year 2025.The shares slumped m